Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Richard MarshakChief Commercial Officer | TriSalus Life SciencesTLSI | Open-market sale | 05/15 | 05/19 | 543 sh | $2.67 | $1,449.81 | −0.4% |
Mary T. SzelaCEO and President | TriSalus Life SciencesTLSI | Open-market buy | 05/15 | 05/18 | 39,682 sh | $2.59 | $102,776.38 | +3.9% |
TriSalus Life SciencesTLSI | Open-market buy | 05/15 | 05/18 | 610,000 sh2 trades | $2.50avg. | $1,525,000 | No record | |
Mats WahlstromDirector | TriSalus Life SciencesTLSI | Open-market buy | 05/15 | 05/18 | 60,000 sh | $2.53 | $151,800 | +68.5% |
Gary B. GordonDirector | TriSalus Life SciencesTLSI | Open-market buy | 05/15 | 05/18 | 10,000 sh | $2.46 | $24,600 | +16.0% |
TriSalus Life SciencesTLSI | Open-market buy | 05/15 | 05/18 | 7,100 sh | $2.43 | $17,253 | +2.6% | |
TriSalus Life SciencesTLSI | Open-market sale | 03/11–03/17 | 03/20 | 20,302 sh2 trades | $3.91avg. | $79,382.94 | −2.6% | |
TriSalus Life SciencesTLSI | Open-market sale | 03/11–03/16 | 03/20 | 3,184 sh3 trades | $4.11avg. | $13,085.45 | −1.9% | |
TriSalus Life SciencesTLSI | Open-market sale | 03/11–03/16 | 03/20 | 3,530 sh3 trades | $4.11avg. | $14,509.08 | −2.8% | |
TriSalus Life SciencesTLSI | Open-market sale | 03/11–03/16 | 03/20 | 3,457 sh3 trades | $4.11avg. | $14,209.66 | −3.0% | |
TriSalus Life SciencesTLSI | Open-market sale | 03/11–03/16 | 03/20 | 3,207 sh3 trades | $4.11avg. | $13,171.3 | −3.2% | |
Mary T. SzelaCEO and President | TriSalus Life SciencesTLSI | Open-market buy | 02/23 | 02/23 | 30,487 sh | $4.10 | $124,996.7 | +4.1% |
TriSalus Life SciencesTLSI | Open-market buy | 02/23 | 02/23 | 361,098 sh2 trades | $4.10avg. | $1,480,501.8 | No record | |
Gary B. GordonDirector | TriSalus Life SciencesTLSI | Open-market buy | 02/23 | 02/23 | 9,756 sh | $4.10 | $39,999.6 | No record |
TriSalus Life SciencesTLSI | Open-market buy | 02/23 | 02/23 | 3,657 sh | $4.10 | $14,993.7 | +1.4% | |
William ValleDirector | TriSalus Life SciencesTLSI | Open-market buy | 02/23 | 02/23 | 30,487 sh | $4.10 | $124,996.7 | No record |
Bryan F. CoxChief of Research | TriSalus Life SciencesTLSI | Open-market sale | 25/05/19 | 25/05/21 | 4,764 sh | $5.18 | $24,677.52 | −3.8% |
Jennifer StevensChief Regulatory Officer | TriSalus Life SciencesTLSI | Open-market sale | 25/05/19 | 25/05/21 | 8,704 sh | $5.18 | $45,086.72 | −10.1% |
Richard MarshakChief Commercial Officer | TriSalus Life SciencesTLSI | Open-market sale | 25/05/19 | 25/05/21 | 6,597 sh | $5.18 | $34,172.46 | −8.7% |
Jodi DevlinChief of Clinical Operations | TriSalus Life SciencesTLSI | Open-market sale | 25/05/19 | 25/05/21 | 4,764 sh | $5.18 | $24,677.52 | −8.3% |